Fill Your Dance Card in March

March 10, 2022 ~ Next Phase Admin ~ Leave a comment

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

As Digital RESI, March 22-24 ramps up, so has interest from the RESI investor community. With over 300 investors already registered for the event, including large pharma/medtech, traditional VCs, family offices/private wealth, and angel groups, this virtual event is shaping up to be buzzing with activity and digital meetings.

What sets RESI apart from many partnering events is the Life Science Nation (LSN) dedicated Investor Research Team responsible for ensuring that each investor’s partnering profiles are comprehensive and up-to-date. This conference is an excellent opportunity for entrepreneurs and founders to expand their network in the industry and connect with investors and strategic partners that are a fit for their company. With less than two weeks left, the partnering activities are at their peak and there is no better time to reach out to investors and book meetings. Register now to connect with these investors at Digital RESI March:

Hot Investor Mandate: Healthcare-Focused VC with USA and Asia Offices Invests in Cutting Edge Life Sciences and Digital Health Solutions Across the Globe

March 10, 2022 ~ Next Phase Admin ~ Leave a comment

An early-stage healthcare venture fund with teams in USA and Asia looks to invest in visionary teams and cutting-edge technologies in both life science and digital health solutions.

The firm’s philosophy is not to take a one-size-fits-all approach to investing. The firm draws from their domain expertise and diversified experiences across the full healthcare spectrum to cover both Biopharma and Digital Health sectors. The firm’s aim is to support companies that can achieve differentiated therapeutic results through truly novel approaches. Combining scientific rigor and strategic connections within our network, the firm provides guidance and add value to our portfolio companies as they grow. The firm is seeking to work with companies from late Seed to Series B, and is open to global opportunities.

The firm is focused on two main investment themes: (1) Life Sciences – the firm looks for sound scientific principles and seek innovative approaches, including breakthrough medicines and platform technologies. The firm’s key areas of interest include neurological diseases, metabolic diseases, and infectious diseases. The firm’s investment team engages with entrepreneurs and companies from early pre-clinical development where there is compelling science with cell and/or animal model proof of concept data and invests through pre-clinical and early clinical proof of concept stages; (2) Digital Health / Bio IT

Digital health is a transformational area in healthcare. The firm looks for technology platforms that enable pertinent scientific insights into drug development and design or enhanced delivery of care from providers to patients. Key areas of interest include synthetic biology, machine learning for drug discovery (proteomics and metabolomics), and tools that help reduce healthcare costs.

The firm is looking for experienced management teams with strong scientific expertise and management skills.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Early-Stage Venture Fund Invests in Novel Therapeutics Companies in Oncology and Autoimmune Diseases, Invests Primarily in Western Europe

March 10, 2022 ~ Next Phase Admin ~ Leave a comment

An active early stage venture fund based in Western Europe has a team composed of experienced professionals in funding, entrepreneurship and therapeutic development. The firm has historically invested in computational biology, next generation tools for protein analysis and cell and gene therapy manufacturing technologies. Majority of technologies in the firm’s portfolio are relating to oncology, but going ahead the firm will consider any indication, if they find technology compelling. The firm has invested primarily in the UK and is willing to consider companies based in the broader Europe and in Switzerland in particular.

The firm is especially interested in companies developing therapeutic approaches, such as state of the art cell therapies that need local manufacturing, cancer vaccines, precision oncology medicine and novel therapies for autoimmune diseases. The firm is primarily interested in early stage, pre-clinical breakthrough technologies seeking seed investment.

The firm takes an active role with the companies in which they invest. The firm frequently leads rounds, and supports and mentors the early stage companies, often either taking a board seat themselves or finding an expert to serve on the board. Apart of building companies, the firm is also interested in the investment in the existing companies, syndicating with other investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Evergreen Fund Invests in Seed to Later-Stage Companies in Medical Devices, Diagnostics, Digital Health, and AI-Related Technologies

March 10, 2022 ~ Next Phase Admin ~ Leave a comment

An evergreen fund focused on seed to later-stage companies building infrastructure and value chains around big data, including but not limited to health and life science data. Initial investment sizes fall within a wide range. Additional capital for follow-on investments is available for portfolio companies. Along with capital, the firm also provides access to their Asian network for later-stage companies needing market expansion (once all other aspects of the company’s business have been resolved). There is not a requirement for a board seat along with investments. The fund is focused on U.S. companies (with a focus on Silicon Valley), but will consider companies globally.

The firm invests in companies that are creating solutions to close the data feedback loop, including capturing data, analytics and instruments/robotics. AME is interested in medical devices, diagnostics and healthcare IT products, with addressable markets of at least $1B. In the diagnostics field, m-health devices and genomics are of particular interest. AME is open to all sub-sectors of health IT including consumer-facing hardware/software, data collection/management and data analytics. The firm will invest in medical devices and diagnostics that require FDA approval, with 510K regulatory pathway being the most common, although devices/services that require different regulatory pathways will also be considered. Companies developing hardware or robotics that automate scientific life science experiments are also of interest. The firm does not make any investments in therapeutics.

There are no formal requirements for management teams, but management teams with experience commercializing products are preferred.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: East Coast-Based Investment Fund Seeks Opportunities in Aging Related Technologies and Digital Health in North America and Israel

March 10, 2022 ~ Next Phase Admin ~ Leave a comment

The firm is an East Coast-based early-stage fund founded in 2019. The firm is affiliated with, but separate from, a leading university leveraging the network of schools and 70,000 + alumni network to help their portfolio companies. The firm invests in technology-based companies in the pre-seed and seed stage, and while they prefer the companies have some revenue, they will invest in pre-revenue companies. The firm invests in several verticals, including SilverTech™ (Seniors and Tech), PropTech, Fintech, Cybersecurity HealthTech and AI/ML. The firm does not invest in therapeutics or medical devices. The firm invests in North America and in Israel, with check size between $50-150K into rounds with a pre-money valuation of $2-10M.

Within HealthTech, the firm invests in SilverTech™ and digital health. For digital health, the company is interested primarily in B2B models, but will invest in B2B2C as well. The firm has a special interest in Agetech, as one of the GPs is third generation senior living owner/operator.

The firm does not lead rounds, but is a very active investor alongside top-tier funds. Due to their strategic value, they are asked to serve in an advisory capacity. The firm prides itself on being a valued strategic partner. The firm will invest in new or seasoned entrepreneurs, who have assembled exceptional teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Everything You Need to Start Partnering Today

March 3, 2022 ~ Next Phase Admin ~ Leave a comment

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Digital RESI March partnering is now open! While it may seem like a simple task to book meetings, successful partnering is a process that takes time, effort, and careful strategy. With over 40 events across a decade, Life Science Nation (LSN) knows how to partner like a pro and offers many free resources, including fundraising bootcamps and informational articles designed to help startups succeed.

RESI attendees also have an added benefit of an investor profile based on the content of the LSN Investor Database, and reading it thoroughly is critical – make sure you are a fit for the investor before reaching out. Additionally, craft a message that is clear and concise with enough information to whet the investor’s appetite for more. Most importantly, follow up!

If you find yourself needing help, or even if you just want to see if there is a new trick for you to learn, read one of the articles we’ve written about partnering in the links below, or sign up to attend our free webinar, Strategies For Successful Partnering, taking place on Tuesday, March 8 at 12PM EST. Happy partnering!

There’s still time to sign up – register here for a chance to meet with the 300+ investor attendees who will take part in Digital RESI March!

Digital RESI June

March 3, 2022March 3, 2022 ~ Next Phase Admin ~ Leave a comment

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the LSN Partnering Conference Series

Part of the success of the Redefining Early Stage Investments (RESI) conference series over the past decade includes its flexible structure and ability to provide valuable partnering resources to early-stage companies and investors alike. While there is no substitute for in-person meetings, RESI’s virtual platform has provided attendees with ease of access around the world. This is why, moving into the new year, RESI will return with both virtual and in-person formats – providing attendees with options to fit their needs.

Digital RESI returns June 7-9 in a virtual format to provide a web-based partnering option to global attendees. RESI Boston will kick off the first in-person event September 20-22, 2022. There is no one-size-fits-all event structure that meets the needs and goals of fundraising executives, early-stage investors, and the many valuable service providers in life science and healthcare, but RESI provides options to attendees who do not need to sacrifice their goals and priorities in 2022 and keeps its promise to connect startups to the early-stage capital and channel partners they need.